Valsartan - CAS 137862-53-4

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
APIs
Product Name
Valsartan
Catalog Number
137862-53-4
CAS Number
137862-53-4
Molecular Weight
435.52 .
Molecular Formula
C24H29N5O3
Quality Standard
EP USP
COA
Inquire
MSDS
Inquire
Structure
CAS 137862-53-4 Valsartan
Specification
Appearance
White crystalline powder
Related Products
  • CAS 58-93-5 Hydrochlorothiazide

    Hydrochlorothiazide
    (CAS: 58-93-5)

    Hydrochlorothiazide is a diuretic medication often used to treat high blood pressure and swelling due to fluid build up.

  • CAS 58-93-5 Hydrochlorothiazide

    Hydrochlorothiazide
    (CAS: 58-93-5)

    Hydrochlorothiazide is a diuretic medication often used to treat high blood pressure and swelling due to fluid build up. It may be used during pregnancy but is ...

Reference Reading
1. Concentrations and mass loadings of cardiovascular pharmaceuticals in healthcare facility wastewaters
Pranav Nagarnaik, Angela Batt and Bryan Boulanger*. J. Environ. Monit., 2010, 12, 2112–2119
At each location three analytes explain 60% or more of the total loading contributed by all measured analytes. Atenolol, valsartan, and hydrochlorothiazide contributed 78% of the total mass loading at the independent living facility; valsartan, atenolol, and norverapamil contributed 89% of the total mass loading at the assisted living facility; diltiazem, desmethyl diltiazem and metoprolol contributed 61% of the total mass loading at the nursing care facility; and valsartan, hydrochlorothiazide, and atenolol contributed 86% of the total mass loading at the hospital.
2. A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment
Susanne Kern, Rebekka Baumgartner, Kathrin Fenner*. J. Environ. Monit., 2010, 12, 2100–2111
We conducted two sampling campaigns and corresponding laboratory batch experiments, an overview of which is provided in Table S1 in the ESI. The goal of the first campaign conducted in 2009 (C09) was the first-tier, qualitative screening for TPs in batch reactors and the verification that the TPs found to form in the batch reactors could also be detected in the effluents of fullscale municipal WWTPs. Seven pharmaceuticals (atenolol, bezafibrate, ketoprofen, metoprolol, ranitidine, valsartan, and venlafaxine) and the biocide carbendazim were selected as test compounds because they represent structurally diverse chemical classes and had been detected in Swiss WWTP influents in the high ng L-1 to low mgL-1 range. Also, results of an earlier survey suggested that these compounds at least partially degraded during activated sludge treatment. The goal of the second campaign in 2010 (C10) was to evaluate the second, quantitative tier predicting effluent concentrations of selected, major TPs. Four pharmaceuticals (atenolol, metoprolol, ranitidine and valsartan) and three of their TPs (atenolol acid, ranitidine-S-oxide, and valsartan acid) were selected for quantitative analysis in accordance with the criteria laid out in Fig. 1. For these four pharmaceuticals comparison of levels at t ¼ 3 h (to account for fast sorption) and t= 24 h of the batch experiments indicated >20% transformation within that time span and chemical reference standards for quantification of their major TPs formed in the batch reactors could be made available.
2005 - BOC Sciences | All rights reserved
DOWNLOAD